This article is more than 5 years old. Information may no longer be current.

Visudyne sales drop more than 40% during first quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

VANCOUVER, British Columbia — Global sales of Visudyne totaled $61.2 million for the first quarter, a 42.7% decrease compared with sales during the first quarter 2006, according to a press release from QLT.

Visudyne (verteporfin) sales in the United States declined 13.7% during the quarter and totaled about $8.4 million. However, U.S. sales appeared to stabilize in January and increased during February and March because of increases in market share of combination therapy, said Bob Butchofsky, QLT's president and CEO, in the release. "Visudyne average daily sales were 105 vials in January, but average daily sales increased in both February and March to 116 and 130 vials, respectively," he said.

QLT will release its full financial results Thursday, the release said.